changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Please find below a list of our press releases.
20 Jan 2014
EKOS Corporation, a BTG International group company today announced the publication of the results of its Ultrasound Accelerated Thrombolysis of Pulmonary Embolism (PE) trial.
26 Nov 2013
BTG plc, today announces that the US Food and Drug Administration (FDA) has approved Varithena™ (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system.
25 Jul 2013
BTG, the specialist healthcare company, today announced the online publication of VANISH-2, a study in which patients with symptomatic and visible varicose veins caused by saphenofemoral junction (SFJ) incompetence were treated with polidocanol endovenous microfoam (PEM).
8 Jul 2013
On 23 May 2013, BTG plc (BTG or the Company), the specialist healthcare company, announced that it had entered into an agreement to buy EKOS Corporation (EKOS) conditional on Hart-Scott-Rodino (HSR) approval in the US.
23 May 2013
BTG plc is pleased to announce that it has entered into an agreement to buy EKOS Corporation.
12 Apr 2013
BTG plc, announces that the New Drug Application (NDA) seeking approval of Varisolve® as a comprehensive treatment for varicose veins, which was submitted to the US Food & Drug Administration (FDA) on 4 February 2013, has been accepted for full review by the FDA.
4 Feb 2013
BTG plc today announces that a New Drug Application (NDA) seeking approval of Varisolve® (polidocanol endovenous microfoam (PEM)) as a comprehensive treatment for varicose veins has been submitted to the US Food & Drug Administration (FDA).
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com